May 2009
Worldwide Biotech;May2009, Vol. 21 Issue 5, p1
Trade Publication
This article reports on the acquisition of an exclusive license for Endomorphin technology by Diamyd Medical in 2009. The technology may be used for the treatment of pain, including neuropathic pain, that occurs in diabetes. It embodies a direct production and release of Endomorfin peptides. Elisabeth Lindner, president and chief executive officer (CEO) of Diamyd Medical, explained the deal.


Related Articles

  • Diamyd Completes Recruitment In Gene Therapy Pain Trial. Sheridan, Cormac // BioWorld International;5/23/2012, p2 

    The article reports on the six percent increase in the value of Diamyd Medical AB stocks after news that it completed recruitment in a Phase II trial of NP2 Enkephalin, its gene therapy treatment for chronic cancer pain. Study results are expected to have an impact on the company's future after...

  • Diamyd Medical: Diamyd Puts Focus on Pain Projects and Reduces Costs.  // Biomedical Market Newsletter;8/23/2011, Vol. 21, p334 

    The article focuses on the shift in the primary development focus of Diamyd Medical AB from diabetes therapy to a portfolio of drug candidates for chronic pain and nervous diseases treatment. It states that the pain portfolio is based on the Nerve Targeting Drug Delivery System's (NTDDS)...

  • Diamyd Medical Reports Results from Phase II Study in Cancer Pain.  // Biomedical Market Newsletter;7/7/2012, Vol. 21, p1 

    The article informs that the drug NP2 Enkephalin developed by Diamyd Medical AB did not meet its primary objective of reducing pain in cancer patients. NP2 Enkephalin is based on the Medical's patented Nerve Targeting Drug Delivery System (NTDDS) platform and delivers the natural painkilling...

  • Diamyd Medical's Phase II study in cancer pain fully recruited.  // Biomedical Market Newsletter;5/25/2012, Vol. 21, p1 

    The article presents information on the Diamyd Medical AB which has recruited the last patient for the treatment of cancer pain with the drug candidate NP2 Enkephalin. It informs that this clinical trial is the first placebo-controlled clinical trial of a drug candidate. As per Peter Zerhouni,...

  • Diamyd Medical: Diamyd Presents Detailed Results of European Phase III Study.  // Biomedical Market Newsletter;7/5/2011, p441 

    The article offers information on the details of European Phase III study of DIAMYD Medical AB regarding the efficacy of their antigen-based diabetes therapy Diamyd®, presented at the 71st Scientific Sessions of the American Diabetes Association in San Diego, California on June 28, 2011. It...

  • Clinic Roundup.  // BioWorld Today;2/11/2011, Vol. 22 Issue 29, p2 

    This section offers news briefs on drug trials. A Phase II trial is being conducted by Diamyd Medical AB for its NP2 Enkephalin drug for the reduction of cancer pain. Enrollment in a Phase I trial of therapeutic caner vaccine DPX-0907 has been completed by Immunovaccine Inc. A Phase II trial of...

  • Clinic Roundup.  // BioWorld Today;5/23/2012, p5 

    This section offers news briefs on clinical trials. A Phase I/II study of Xerecept (corticorelin acetate) in pediatric patients who are dependent on the steroid Decadron to treat peritumoral brain edema associated with cerebral tumors has been completed by Celtic Pharmaceutical Holdings LP....

  • Diamyd Climbs on $625M Type I Diabetes Deal.  // Bioworld Week;6/28/2010, Vol. 18 Issue 26, p4 

    The article reports on the deal to develop the Type I diabetes, entered by Diamyd Medical AB in Sweden.

  • Information about Summons to the Annual General Meeting of Diamyd Medical AB.  // Biomedical Market Newsletter;11/16/2011, Vol. 21, p138 

    The article offers information on the Annual General Meeting of Diamyd Medical AB, to be held on December 7, 2011.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics